45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Recent Children's Oncology Group (COG) trials tested the efficacy of reduced therapy in an effort to lessen late effects compared to the Intergroup Rhabdomyosarcoma Study (IRS) IV regimen with associated hematologic and hepatic toxicity, and infertility. Here, we analyze the efficacy of 45 Gray...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2017-09, Vol.64 (9)
Main Authors: Ermoian, Ralph P, Breneman, John, Walterhouse, David O, Chi, Yueh-Yun, Meza, Jane, Anderson, James, Hawkins, Douglas S, Hayes-Jordan, Andrea A, Parham, David M, Yock, Torunn I, Donaldson, Sarah S, Wolden, Suzanne L
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Child
Child, Preschool
Combined Modality Therapy
Female
History, Ancient
Humans
Kaplan-Meier Estimate
Male
Orbital Neoplasms - drug therapy
Orbital Neoplasms - mortality
Orbital Neoplasms - radiotherapy
Radiation Dosage
Radiotherapy - methods
Rhabdomyosarcoma, Embryonal - drug therapy
Rhabdomyosarcoma, Embryonal - mortality
Rhabdomyosarcoma, Embryonal - radiotherapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent Children's Oncology Group (COG) trials tested the efficacy of reduced therapy in an effort to lessen late effects compared to the Intergroup Rhabdomyosarcoma Study (IRS) IV regimen with associated hematologic and hepatic toxicity, and infertility. Here, we analyze the efficacy of 45 Gray (Gy) local radiotherapy (RT) in patients with Group III orbital embryonal rhabdomyosarcoma (ERMS) enrolled on the COG low-risk study ARST0331. Sixty-two patients with Group III orbital ERMS were treated on ARST0331 with four cycles of vincristine (VCR), dactinomycin (DACT), and cyclophosphamide (CPM; VAC, total cumulative CPM dose 4.8 g/m ) followed by four cycles of VCR and DACT over 22 weeks. Forty-five Gray of radiation was administered in 25 fractions beginning at week 13 of therapy. Fifty-three patients were evaluable for this response analysis; seven had missing week 12 response evaluation data and two had progressive disease prior to starting RT. Median follow-up was 7.8 years. None of the 15 patients with radiographic complete response (CR) compared to 6 of the 38 patients with
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.26540